ADPT (Adaptive Biotechnologies) Institutional Ownership: 101.97% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADPT Adaptive Biotechnologies Corp ADPT
67 GF Score
Price $21.45
GF Value $10.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Institutional Ownership?

Adaptive Biotechnologies ADPT +1.90% 67 Institutional Ownership is 101.97% as of Jul. 15, 2026. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adaptive Biotechnologies's institutional ownership is 101.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adaptive Biotechnologies's Insider Ownership is 6.50%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adaptive Biotechnologies's Float Percentage Of Total Shares Outstanding is 79.20%.

Adaptive Biotechnologies Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Institutional Ownership Chart

Adaptive Biotechnologies Historical Data

The historical data trend for Adaptive Biotechnologies can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 59.47 59.21 60.06 61.24 60.13 60.71 54.94 55.35 54.43 13.75
ADPT
67GF Score
Adaptive Biotechnologies Corp ADPT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 101.97% mean?
Adaptive Biotechnologies (ADPT) has a Institutional Ownership of 101.97% as of Jul. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Adaptive Biotechnologies and its competitors.
Is Adaptive Biotechnologies' Institutional Ownership too high?
Adaptive Biotechnologies' current Institutional Ownership is 101.97%. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Institutional Ownership compare to GRAL and WGS?
Adaptive Biotechnologies' Institutional Ownership of 101.97% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Diagnostics & Research company?
A good Institutional Ownership depends on the Medical Diagnostics & Research industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Institutional Ownership is 101.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.05, compared to a current price of $21.45 — trading 113.4% above its estimated fair value. The current Institutional Ownership is 101.97%. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Institutional Ownership is 101.97% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $21.45 is trading 113.4% above its estimated GF Value™ of $10.05. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Institutional Ownership: 101.97%
  • GF Value™: $10.05 vs. price of $21.45 (113.4% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
67GF Score

Get the complete analysis for ADPT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.45
Price
$10.05
GF Value